These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 35656940)
1. Impact of minor bleeds on confidence in anticoagulation therapy, adherence to treatment and quality of life in patients using a non-vitamin K antagonist oral anticoagulant for atrial fibrillation. Mitrovic D; Veeger N; van Roon E Curr Med Res Opin; 2022 Sep; 38(9):1485-1488. PubMed ID: 35656940 [TBL] [Abstract][Full Text] [Related]
2. Costs of minor bleeds in atrial fibrillation patients using a non-vitamin K antagonist oral anticoagulant. Mitrovic D; Plomp M; Folkeringa R; Veeger N; Feenstra T; van Roon E Curr Med Res Opin; 2021 Sep; 37(9):1461-1466. PubMed ID: 33989088 [TBL] [Abstract][Full Text] [Related]
3. Minor bleeding in patients with atrial fibrillation using a non-vitamin-K antagonist oral anticoagulant. Mitrovic D; Folkeringa R; Veeger N; van Roon E Curr Med Res Opin; 2020 Oct; 36(10):1571-1576. PubMed ID: 32573287 [TBL] [Abstract][Full Text] [Related]
4. Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study. Forslund T; Wettermark B; Andersen M; Hjemdahl P Europace; 2018 Mar; 20(3):420-428. PubMed ID: 28177459 [TBL] [Abstract][Full Text] [Related]
5. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]). Steinberg BA; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Peterson ED; Piccini JP; Am J Cardiol; 2017 May; 119(10):1590-1595. PubMed ID: 28363354 [TBL] [Abstract][Full Text] [Related]
6. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy. De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115 [TBL] [Abstract][Full Text] [Related]
7. The optimal drug adherence to maximize the efficacy and safety of non-vitamin K antagonist oral anticoagulant in real-world atrial fibrillation patients. Kim D; Yang PS; Jang E; Yu HT; Kim TH; Uhm JS; Kim JY; Sung JH; Pak HN; Lee MH; Lip GYH; Joung B Europace; 2020 Apr; 22(4):547-557. PubMed ID: 31598651 [TBL] [Abstract][Full Text] [Related]
8. Drug Utilization Pattern of Oral Anticoagulants in Patients with Atrial Fibrillation: A Nationwide Population-Based Study in Korea. Lee MY; Han S; Bang OY; On YK; Jang SW; Han S; Ryu J; Park YJ; Kang S; Suh HS; Kim YH Adv Ther; 2022 Jul; 39(7):3112-3130. PubMed ID: 35524839 [TBL] [Abstract][Full Text] [Related]
9. Community pharmacy-based study of adherence to non-vitamin K antagonist oral anticoagulants. Capiau A; Mehuys E; Van Tongelen I; Christiaens T; De Sutter A; Steurbaut S; Moudallel S; Rydant S; Vrijens B; de Backer TLM; Boussery K Heart; 2020 Nov; 106(22):1740-1746. PubMed ID: 32576607 [TBL] [Abstract][Full Text] [Related]
10. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group. Pharithi RB; Ranganathan D; O'Brien J; Egom EE; Burke C; Ryan D; McAuliffe C; Vaughan M; Coughlan T; Morrissey E; McHugh J; Moore D; Collins R Ir J Med Sci; 2019 Feb; 188(1):101-108. PubMed ID: 29860595 [TBL] [Abstract][Full Text] [Related]
11. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Steffel J; Verhamme P; Potpara TS; Albaladejo P; Antz M; Desteghe L; Haeusler KG; Oldgren J; Reinecke H; Roldan-Schilling V; Rowell N; Sinnaeve P; Collins R; Camm AJ; Heidbüchel H; Eur Heart J; 2018 Apr; 39(16):1330-1393. PubMed ID: 29562325 [TBL] [Abstract][Full Text] [Related]
12. Safety of once- or twice-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with nonvalvular atrial fibrillation: A NOAC-TR study. Emren SV; Zoghi M; Berilgen R; Özdemir İH; Çelik O; Çetin N; Enhoş A; Köseoğlu C; Akyüz A; Doğan V; Levent F; Dereli Y; Doğan T; Başaran Ö; Karaca I; Karaca Ö; Otlu YÖ; Özmen Ç; Coşar S; Sümerkan M; Gürsul E; İnci S; Onrat E; Ergene O Bosn J Basic Med Sci; 2018 May; 18(2):185-190. PubMed ID: 28968197 [TBL] [Abstract][Full Text] [Related]
13. Utilization of oral anticoagulants in Korean nonvalvular atrial fibrillation patients. Song HY; Son KB; Shin JY; Bae S Int J Clin Pharm; 2019 Dec; 41(6):1434-1441. PubMed ID: 31522377 [TBL] [Abstract][Full Text] [Related]
14. Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation. Lee SR; Lee YS; Park JS; Cha MJ; Kim TH; Park J; Park JK; Lee JM; Kang KW; Shim J; Uhm JS; Kim J; Kim C; Kim JB; Park HW; Joung B; Choi EK Yonsei Med J; 2019 Mar; 60(3):277-284. PubMed ID: 30799590 [TBL] [Abstract][Full Text] [Related]
15. Treatment Changes among Users of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation. Hellfritzsch M; Husted SE; Grove EL; Rasmussen L; Poulsen BK; Johnsen SP; Hallas J; Pottegård A Basic Clin Pharmacol Toxicol; 2017 Feb; 120(2):187-194. PubMed ID: 27580086 [TBL] [Abstract][Full Text] [Related]
16. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Steffel J; Verhamme P; Potpara TS; Albaladejo P; Antz M; Desteghe L; Georg Haeusler K; Oldgren J; Reinecke H; Roldan-Schilling V; Rowell N; Sinnaeve P; Collins R; Camm AJ; Heidbüchel H; Europace; 2018 Aug; 20(8):1231-1242. PubMed ID: 29562331 [TBL] [Abstract][Full Text] [Related]
17. Minor bleeding affects the level of knowledge in patients with atrial fibrillation on oral anticoagulant therapy. Metzgier-Gumiela A; Skonieczny G; Konieczyńska M; Desteghe L; Heidbuchel H; Undas A Int J Clin Pract; 2020 Jun; 74(6):e13483. PubMed ID: 32003070 [TBL] [Abstract][Full Text] [Related]
18. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Heidbuchel H; Verhamme P; Alings M; Antz M; Diener HC; Hacke W; Oldgren J; Sinnaeve P; Camm AJ; Kirchhof P Europace; 2015 Oct; 17(10):1467-507. PubMed ID: 26324838 [TBL] [Abstract][Full Text] [Related]
19. Clinical events preceding switching and discontinuation of oral anticoagulant treatment in patients with atrial fibrillation. Hellfritzsch M; Grove EL; Husted SE; Rasmussen L; Poulsen BK; Johnsen SP; Hallas J; Pottegård A Europace; 2017 Jul; 19(7):1091-1095. PubMed ID: 28641379 [TBL] [Abstract][Full Text] [Related]
20. Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study. Moreno-Arribas J; Bertomeu-González V; Anguita-Sanchez M; Cequier Á; Muñiz J; Castillo J; Sanchis J; Roldán I; Marín F; Bertomeu-Martínez V; J Cardiovasc Pharmacol Ther; 2016 Mar; 21(2):150-6. PubMed ID: 26229096 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]